REG - Arecor Therapeutics - BOARD CHANGE

Arecor TherapeuticsAnnouncement

23/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240423:nRSW5889La&default-theme=true

RNS Number : 5889L  Arecor Therapeutics PLC  23 April 2024

Arecor Therapeutics plc

("Arecor" or the "Company")

 

BOARD CHANGE

 

ARECOR ANNOUNCES SUSAN LOWTHER TO STEP DOWN AS CHIEF FINANCIAL OFFICER

 

Cambridge, UK, 23 April 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announced that Susan Lowther has decided to step down from her role as
Chief Financial Officer, Company Secretary and as a Board Director, to pursue
new opportunities.

 

A search for Susan's successor is underway and her last day with Arecor is
expected to be on the 22 July, to ensure an effective handover.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "On behalf of the Board
and all at Arecor, I want to thank Susan for her contributions over the past
five years, in our transition to a public company and growth as a business. We
wish her every success in her future plans."

 

Susan Lowther, Chief Financial Officer of Arecor, said: "I am proud to have
been Arecor's first Chief Financial Officer and of our achievements as a
business, and believe the Company is well placed for further growth. I will
watch the future progress with interest."

 

-ENDS-

 

 

For more information, please contact:

 

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Financial Advisor)
 Nigel Barnes, Satheesh Nadarajah                Tel: +44 (0)203 705 9321

 David Wilson, Claes Spang

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville     Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUUAKRSBUSUAR